LifeSci Biotechnology Clinical Trials Index
Effective at the market close on July 23, 2025, VERV will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights.
On June 17, 2025, Verve Therapeutics announced it would be acquired by Eli Lilly for $10.50/share in cash plus up to $3.00/share in a CVR (contingent value right).